Real-world study on the application and influencing factors of SGLT-2i in patients with heart failure with preserved ejection fraction
- VernacularTitle:SGLT-2i在射血分数保留型心力衰竭患者中使用现状及影响因素的真实世界研究
- Author:
Tiantian CAI
1
;
Junlong CHEN
2
;
Yihang ZHANG
2
;
Siyi HE
2
;
Jian LIU
2
;
Ruonan XIAO
2
;
Shangjian LUO
2
;
Lei GAO
2
;
Dongying ZHANG
3
Author Information
1. Dept. of Endocrinology，the First Affiliated Hospital of Chongqing Medical University，Chongqing 400042，China
2. Dept. of Cardiology，the First Affiliated Hospital of Chongqing Medical University，Chongqing 400042，China
3. Dept. of Cardiology，Chongqing University Central Hospital，Chongqing 400010，China
- Publication Type:Journal Article
- Keywords:
sodium-dependent glucose transporters 2 inhibitors;
heart failure with preserved ejection fraction;
diabetes
- From:
China Pharmacy
2026;37(8):1045-1049
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To investigate the application and influencing factors of sodium-dependent glucose transporters 2 inhibitors（SGLT-2i） in patients with heart failure with preserved ejection fraction（HFpEF） in the real world. METHODS Data from 358 patients with HFpEF who were hospitalized at the First Affiliated Hospital of Chongqing Medical University from May 2023 to May 2024 were retrospectively collected. The patients were divided into the SGLT-2i group and the non-SGLT-2i group based on whether they were prescribed SGLT-2i upon discharge. Baseline characteristics， comorbidities， and differences in drug treatment were compared between the two groups. Based on univariate analysis， multivariate Logistic regression analysis was performed to identify independent influencing factors of SGLT-2i use in patients with HFpEF， followed by further stratified analysis. RESULTS Among 358 HFpEF patients， the overall utilization rate of SGLT-2i was 33.5%. Combined with type 2 diabetes [OR＝9.063，95%CI（4.924-16.679） ] ， atrial fibrillation [OR＝3.135，95%CI（1.590-6.178） ] ， coronary artery heart disease [OR＝1.888，95%CI（1.072-3.327） ] and the use of loop diuretics [OR＝3.822， 95%CI （1.588-9.200） ] were all independent influencing factors for the use of SGLT-2i in patients with HFpEF （ P ＜0.05）. The results of the stratified descriptive analysis were consistent with those of the multivariate analysis， showing a higher utilization rate of SGLT-2i among patients with concomitant T2DM，atrial fibrillation， coronary artery heart disease， and those receiving loop diuretics （ P ＜0.05）； whereas the utilization rate of SGLT-2i was comparable across patients with different levels of renal function （ P ＞0.05）. CONCLUSIONS In the real-world clinical practice， the utilization of SGLT-2i in patients with HFpEF remains suboptimal， and treatment coverage still needs to be improved. Their use of SGLT-2i is primarily influenced by the presence of type 2 diabetes， atrial fibrillation， coronary artery heart disease， and the use of loop diuretics.
